This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

BeneFIX (nonacog alfa) Prescribing Information for Great Britain click here. BeneFIX (nonacog alfa) Prescribing Information for Northern Ireland click here.
​​​​​​​
Adverse event reporting can be found at the bottom of this page.    

​​​​​​​BeneFIX® (nonacog alfa) is recombinant coagulation factor IX indicated for the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency). BeneFIX® can be used for all age groups.1  

How BeneFIX® works    

BeneFIX® (nonacog alfa) contains recombinant coagulation factor IX and has functional characteristics comparable to those of endogenous factor IX. As factor IX activity is greatly reduced in patients with haemophilia B, replacement therapy is necessary.1   

Haemophilia B is a sex-linked hereditary coagulopathy resulting from decreased factor IX that causes profuse bleeding into joints, muscles or internal organs. Replacement therapy increases the plasma factor IX levels, temporarily correcting the factor deficiency and, consequently, the bleeding tendencies.1    

When infused into a patient with haemophilia B, factor IX is activated by factor VII/tissue factor complex in the extrinsic pathway, as well as factor XIa in the intrinsic coagulation pathway. Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X. Activated factor X converts prothrombin into thrombin. Thrombin then converts fibrinogen into fibrin, and a clot is formed.1  

How does BeneFIX® replace factor IX?  

Explore More

Heritage  

BeneFIX® has more than 20 years’ experience in haemophilia B, building on a proud heritage in haemophilia care.1

Find out more

Purification

The process used to manufacture BeneFIX® eliminates the risk of blood-borne pathogens, such as HIV, hepatitis viruses, parvovirus and prions that cause variant Creutzfeldt-Jakob disease.3

Read more

Safety profile

BeneFIX® has a well-documented safety profile in both adults and children.1

Read more

** This is an optional area where footnotes can live.

Clinical efficacy

Access data on the clinical efficacy of BeneFIX® for on-demand treatment and prophylaxis.  

Find out more

** This is an optional area where footnotes can live.


References
  1. BeneFIX® Summary of Product Characteristics. For Great Britain, available here. For Northern Ireland, available here.
  2. Bowen D. Mol Pathol. 2002;55(2):127–44.  
  3. Adamson S et al. Semin Hematol. 1998;35(2 Suppl 2):22–27.  
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
​​​​​​​Adverse events should also be reported to Pfizer Medical Information on 01304 616161.

PP-BEN-GBR-0486. September 2021.

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No